Literature DB >> 20034203

Patterns of benzodiazepine use in a Canadian population sample.

Eleonora Esposito1, Corrado Barbui, Scott B Patten.   

Abstract

AIM: The objective of this study was to identify clinical and demographic factors that may be associated with benzodiazepine treatment, to describe the reported reasons for use of these medications and to appraise the pattern of use in relation to standard guidelines in a general population sample.
METHODS: Telephone survey methods were employed to select a sample of 3345 people between the ages of 18 and 64. A computer assisted telephone interview, including the Mini Neuropsychiatric Diagnostic Interview (MINI), was administered. Estimates were weighted for design features and population demographics.
RESULTS: The overall prevalence of benzodiazepines use was 3.3% (95% confidence interval [CI] 2.6 to 4.1%). There was a higher frequency of medication use in women than men, among respondents who were widowed, separated or divorced, and those with lower levels of education. In relation to MINI diagnosis, diagnoses of Panic Disorder and Major Depression increased the probability of taking benzodiazepines. The reported main reason for use was "Sleep disorders" (68.9%), "Anxiety" (35.8%), "Depression" (27.8%) and "Pain management" (21.2%). More than 80% of subjects were taking benzodiazepines for more than one year.
CONCLUSIONS: When compared to previous estimates, the lower frequency of benzodiazepines use suggests that there has been improvement in their evidence-based use at a population level. However our results once more confirm the difficulty stopping the use of these medications once they have been started. Further randomized control studies may help clinicians in having a better practical approach to rational benzodiazepine use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20034203

Source DB:  PubMed          Journal:  Epidemiol Psichiatr Soc        ISSN: 1121-189X


  11 in total

Review 1.  Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995.

Authors:  Yoko Murphy; Emily Wilson; Elliot M Goldner; Benedikt Fischer
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

2.  Association between use of benzodiazepines and risk of fractures: a meta-analysis.

Authors:  D Xing; X L Ma; J X Ma; J Wang; Y Yang; Y Chen
Journal:  Osteoporos Int       Date:  2013-09-07       Impact factor: 4.507

3.  Benzodiazepine use in breast cancer survivors: findings from a consecutive series of 1,000 patients.

Authors:  Rakhee Vaidya; Richa Sood; Nina Karlin; Aminah Jatoi
Journal:  Oncology       Date:  2011-09-02       Impact factor: 2.935

Review 4.  Anxiety and substance use disorders: co-occurrence and clinical issues.

Authors:  Florence Vorspan; Wajdi Mehtelli; Gaël Dupuy; Vanessa Bloch; Jean-Pierre Lépine
Journal:  Curr Psychiatry Rep       Date:  2015-02       Impact factor: 5.285

5.  Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis.

Authors:  Ruth Ann Marrie; John D Fisk; Randy Walld; James M Bolton; Jitender Sareen; Scott B Patten; Alexander Singer; Lisa M Lix; Carol A Hitchon; Renée El-Gabalawy; Alan Katz; James J Marriott; Charles N Bernstein
Journal:  Front Neurol       Date:  2022-04-14       Impact factor: 4.086

Review 6.  Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States.

Authors:  T P Khong; F de Vries; J S B Goldenberg; O H Klungel; N J Robinson; Luisa Ibáñez; H Petri
Journal:  Calcif Tissue Int       Date:  2012-05-08       Impact factor: 4.333

7.  Benzodiazepine use among adults residing in the urban settlements of Karachi, Pakistan: a cross sectional study.

Authors:  Saleem P Iqbal; Syed Ahmer; Salima Farooq; Yasmin Parpio; Ambreen Tharani; Rashid A M Khan; Mohammad Zaman
Journal:  Subst Abuse Treat Prev Policy       Date:  2011-08-01

Review 8.  Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review.

Authors:  André S Pollmann; Andrea L Murphy; Joel C Bergman; David M Gardner
Journal:  BMC Pharmacol Toxicol       Date:  2015-07-04       Impact factor: 2.483

9.  Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial.

Authors:  Dan J Stein
Journal:  Adv Ther       Date:  2015-01-27       Impact factor: 3.845

10.  Patterns of benzodiazepines use in primary care adults with anxiety disorders.

Authors:  Marie-Michèle Tanguay Bernard; Mireille Luc; Jean-Daniel Carrier; Louise Fournier; Arnaud Duhoux; Elodie Côté; Olivier Lessard; Catherine Gibeault; Christian Bocti; Pasquale Roberge
Journal:  Heliyon       Date:  2018-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.